Jay L. Koyner, MD, is a Professor of Medicine in the Section of Nephrology at the University of Chicago where he also serves as the Medical Director of the Inpatient Dialysis Unit, Director of ICU Nephrology and the Associate Program Director of the Nephrology-Critical Care Fellowship. His clinical and research focus centers on critical care nephrology including the earlier detection of acute kidney injury (AKI) using machine-learning risk scores and novel biomarkers of tubular injury as well as improving the care delivery of patients with AKI especially those receiving continuous renal replacement therapy.
For nearly two decades Dr. Koyner has been a national and international leader in AKI research. He has contributed to the development and FDA validation of several new biomarkers as well as the standardization of the furosemide stress test, all of which can be used for more accurate prediction for the development of severe AKI. Having worked to bring these tools from research studies to clinical use his work has improved the care of patients at risk for AKI as well as those with established early AKI.
In addition to his research efforts, Dr. Koyner is an accomplished educator having created and directed the Nephrology fellowship’s Intensive Care Unit rotations. On the national level he has directed the American Society of Nephrology’s Critical Care Nephrology pre-course and edited of the Nephrology Self-Assessment Program (NephSAP) for Acute Kidney Injury and Critical Care Nephrology. More recently he has served as the primary editor of the Handbook of Critical Care Nephrology.
Dr. Koyner is actively involved in training the next generation of critical care nephrologists as well as residents, medical students and undergraduates. He has published over 100 peer reviewed articles, book chapters and consensus care documents and has served on the editorial boards of several prominent nephrology and critical care journals.
As the medical director of the inpatient acute dialysis unit, he continues to innovate and provide cutting edge care to hospitalized patients at the University of Chicago. This includes establishing a Molecular Adsorbent Recirculating System (MARS) program to improve the care of patients with combined liver-kidney injury as well as establishing protocols to assist in administrating Chimeric Antigen Receptor T-Cell (CAR-T) therapy to patients with end-stage kidney disease and dialysis requiring AKI.
The University of Chicago
Chicago. IL
- Nephrology
2006
The University of Chicago
Chicago
- Internal Medicine
2004
Stony Brook School of Medicine
Stony Brook, NY
MD - Medicine
2001
The Johns Hopkins University
Baltimore, MD
BA - Biophysics
1996
Multicenter Development and Validation of a Multimodal Deep Learning Model to Predict Moderate to Severe Acute Kidney Injury.
Multicenter Development and Validation of a Multimodal Deep Learning Model to Predict Moderate to Severe Acute Kidney Injury. Clin J Am Soc Nephrol. 2025 Apr 15.
PMID: 40232856
Correction: A common longitudinal intensive care unit data format (CLIF) for critical illness research.
Correction: A common longitudinal intensive care unit data format (CLIF) for critical illness research. Intensive Care Med. 2025 Apr; 51(4):836-839.
PMID: 40163136
A common longitudinal intensive care unit data format (CLIF) for critical illness research.
A common longitudinal intensive care unit data format (CLIF) for critical illness research. Intensive Care Med. 2025 Mar; 51(3):556-569.
PMID: 40080116
Acute Kidney Injury and Critical Care Nephrology.
Acute Kidney Injury and Critical Care Nephrology. Adv Kidney Dis Health. 2025 Jan; 32(1):12-23.
PMID: 40175025
Can we use artificial intelligence to better treat acute kidney injury?
Can we use artificial intelligence to better treat acute kidney injury? Intensive Care Med. 2025 Jan; 51(1):160-162.
PMID: 39661141
Biomarker Enrichment in Sepsis-Associated Acute Kidney Injury: Finding High-Risk Patients in the Intensive Care Unit.
Biomarker Enrichment in Sepsis-Associated Acute Kidney Injury: Finding High-Risk Patients in the Intensive Care Unit. Am J Nephrol. 2024; 55(1):72-85.
PMID: 37844555
Real-World Use of AKI Biomarkers: A Quality Improvement Project Using Urinary Tissue Inhibitor Metalloprotease-2 and Insulin-Like Growth Factor Binding Protein 7 ([TIMP-2]*[IGFBP7]).
Real-World Use of AKI Biomarkers: A Quality Improvement Project Using Urinary Tissue Inhibitor Metalloprotease-2 and Insulin-Like Growth Factor Binding Protein 7 ([TIMP-2]*[IGFBP7]). Am J Nephrol. 2023; 54(7-8):281-290.
PMID: 37356428
Management of Respiratory Failure: Ventilator Management 101 and Noninvasive Ventilation.
Management of Respiratory Failure: Ventilator Management 101 and Noninvasive Ventilation. Clin J Am Soc Nephrol. 2022 04; 17(4):572-580.
PMID: 35273008
Renal Considerations in COVID-19: Biology, Pathology, and Pathophysiology.
Renal Considerations in COVID-19: Biology, Pathology, and Pathophysiology. ASAIO J. 2021 10 01; 67(10):1087-1096.
PMID: 34191753
Not All Sepsis-Associated Acute Kidney Injury Is the Same: There May Be an App for That.
Not All Sepsis-Associated Acute Kidney Injury Is the Same: There May Be an App for That. Clin J Am Soc Nephrol. 2020 11 06; 15(11):1543-1545.
PMID: 33034570
Mid-Career Award
American Society of Nephrology
2019